Share
1,953 Posts.
lightbulb Created with Sketch. 187
clock Created with Sketch. 26/02/18
21:57
Share
Originally posted by Creaturemagic
↑
Full disclosure I bought AC8 at 98cents and sold at 54 cents, so I did make a loss on AC8 as I was impatient. However, I'm not here because I'm spiteful or anything, I've been watching the rise since I sold and just wanted to shed some light on my current thoughts. I'm a filthy non-holder and so I'm sure some holders won't like this post but I'm just giving the forum another perspective.$206.2 Million . The company reported $0.00 revenue for the 6 months of FY2018, with $119k being made through interest. Now I understand they have $12 million in the bank, which at a cash burn rate of $1.8 million for the current quarter could sustain them for another year or two, but just let me show you some other companies, their market caps and their revenue.$856 Million . According to their 4C, BIG had a yearly revenue of $37 Million.valuation of $23 Million in market cap per $1 Million in revenue. $1.2 billion and reported $49 Million revenue for the half year ended December 2017. This gives a valuation of $24 Million per $1 Million of revenue for the half year. Or on an average of $25 million per quarter, a market valuation of $48 million per $1 million revenue in the quarter. $100 Million with a 4C showing $392,000 revenue for the quarter. Giving a valuation of $255k per $10k revenue or $255 million per $1 million revenue. $280 Million based on a 4C that shows $2.084 Million revenue for the quarter . Giving a valuation of approx. $140 million per $1 million revenue. $767 million. December quarterly shows $1.871 Million revenue for the quarter. Giving a valuation of $409.9 Million per $1 million revenue. $101.5 million in value per $1 million in revenue. $98.5 million market cap value per $1 million in revenue generation. $79 million per $1 million of revenue generated in a quarter.
Expand
How about you compare apples with apples? At least a company in the same healthcare or medicinal cannabis industry? I find it hard to believe that you’re basing your valuation against established companies rather than ones in the same speculative space. Indeed, making those types of comparisons neglect to truly value any company within a nascent MC sector especially given the whole industry is still fighting bureaucrats with prohibitive restrictions in multiple jurisdictions. Once restrictions and red tape have been relaxed in relation to MC distribution and prescription, revenue will come. Perhaps then your valuation will be met.
